Bausch+Lomb Results Presentation Deck slide image

Bausch+Lomb Results Presentation Deck

Reconciliation of Reported Revenue to Constant Currency Revenue¹ and Constant Currency Revenue Growth¹ ($M) Contact Lens Consumer² Surgical Consumables4 Surgical Implantables Surgical Equipment Lumify Ocuvite + PreserVision Artelac Contact Lens (excluding impact of distribution facility disruptions") Premium IOLS International Pharmaceuticals² Vyzulta BAUSCH + LOMB 1. 2. 3. 4. 5. Calculation of Constant Currency Revenue for the Three Months Ended June 30, 2023 June 30, 2022 Revenue as Reported 215 431 102 47 46 43 104 36 230 11 82 15 Changes in Exchange Rates³ 6 9 1 1 6 1 2 Constant Currency Revenue (Non- GAAP)¹ 221 440 103 47 46 43333 105 36 236 12 84 15 Revenue as Reported 213 375 93 49 42 35 94 29 213 9 70 12 Change in Reported Revenue Amount 2 56 9 (2) 4 8 10 7 17 2 12 3 Pct. 1% 15% 10% -4% 10% 23% 11% 24% 8% 22% 17% 25% Change in Constant Currency Revenue Amount 8 65 10 (2) 4 8 11 7 23 3 14 3 Pct. 4% 17% 11% -4% 10% 23% 12% 24% 10% 33% 20% 25% This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and Non-GAAP Appendix for further information on non-GAAP measures and ratios. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues t their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.. Contact Lens Revenue Impact of distribution facility disruptions is approximately $15M. 34
View entire presentation